← Leaderboards
Richard P Junghans
Beth Israel Deaconess Medical Center
$3,490,049
Attributed
$3,490,049
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $630.6K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,772,549 · 9
FDA$717,500 · 1
By mechanism
R01$2,131,095 · 3
R21$897,189 · 3
R56$400,205 · 1
K04$61,560 · 1
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Chen Sabrina Tan$4,716,945
- Bruce J Dezube$965,277
- Chakar N Adra$365,400
- Norman L Letvin$50,955,616
- Henry Koziel$4,116,745
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical Trial Phase IClinical ResearchHuman Therapy EvaluationNeoplasm /Cancer ImmunotherapyInterleukin 2T LymphocyteAntitumor AntibodyDrug Screening /EvaluationImmunoglobulin GT Cell ReceptorReceptor ExpressionDrug Adverse EffectLeukemiaLymphomaMonoclonal AntibodyAdenocarcinomaCombination Cancer TherapyTissue /Cell CultureHiv InfectionsFusion GeneAnergyFailure (Biologic Function)Aids/Hiv Problem
Grant awards (28)
Towards a new clinical trial Advanced infection proof anti HIV gene modified T ce$230,165
R56 · FY2013 · AI · contact PI
Towards a new clinical trial Advanced infection proof anti HIV gene modified T ce$170,040
R56 · FY2013 · AI · contact PI
ANTI-CEA DESIGNER T CELLS IN GASTRIC CANCER, PHASE I TR*$200,000
R01 · FY2009 · FD · contact PI
ANTI-CEA DESIGNER T CELLS IN GASTRIC CANCER, PHASE I TR*$37,500
R01 · FY2009 · FD · contact PI
Potent Designer T cells for HIV/AIDS Immunotherapy$209,689
R21 · FY2008 · AI · contact PI
ANTI-CEA DESIGNER T CELLS IN GASTRIC CANCER, PHASE I TR*$200,000
R01 · FY2008 · FD · contact PI
Potent Designer T cells for HIV/AIDS Immunotherapy$256,500
R21 · FY2007 · AI · contact PI
Designer T Cell Therapy for PML$350,564
R01 · FY2006 · AI · contact PI
ANTI-CEA DESIGNER T CELLS IN GASTRIC CANCER, PHASE I TR*$280,000
R01 · FY2006 · FD · contact PI
Designer T Cell Therapy for PML$359,000
R01 · FY2005 · AI
Designer T Cell Therapy for PML$359,000
R01 · FY2004 · AI
Infulence of DM Locus on a Distant Gene (FCGRT) in Myot*$85,000
R21 · FY2002 · AR
T CELLS MODIFIED W/ CHIMERIC ANTICEA IGTCR IN ADENOCARCINOMA$0
M01 · FY2002 · RR
HUMANIZED ANTI TAC ANTIBODY THERAPY IN LEUKEMIA/ LYMPHOM$0
M01 · FY2002 · RR
NEO ANTIGEN AND IMMUNOBIOLOGY OF MEDULLARY BREAST CANCER$130,500
R21 · FY2001 · CA
DM Locus in Myotonic Dystrophy$85,000
R21 · FY2001 · AR
T CELLS MODIFIED W/ CHIMERIC ANTICEA IGTCR IN ADENOCARCINOMA$0
M01 · FY2001 · RR
HUMANIZED ANTI TAC ANTIBODY THERAPY IN LEUKEMIA/ LYMPHOM$0
M01 · FY2001 · RR
ANTICEA IGTCR MODIFIED T CELLS FOR CANCER THERAPY$340,647
R01 · FY2000 · CA
NEO ANTIGEN AND IMMUNOBIOLOGY OF MEDULLARY BREAST CANCER$130,500
R21 · FY2000 · CA
TARGETED IMMUNOTHERAPIES IN CANCER$61,560
K04 · FY2000 · CA
ANTICEA IGTCR MODIFIED T CELLS FOR CANCER THERAPY$4,384
R01 · FY2000 · CA
HUMANIZED ANTI TAC ANTIBODY THERAPY IN LEUKEMIA/ LYMPHOM$0
M01 · FY2000 · RR
T CELLS MODIFIED W/ CHIMERIC ANTICEA IGTCR IN ADENOCARCINOMA$0
M01 · FY2000 · RR
T CELLS MODIFIED W/ CHIMERIC ANTICEA IGTCR IN ADENOCARCINOMA$0
M01 · FY2000 · RR
T CELLS MODIFIED W/ CHIMERIC ANTICEA IGTCR IN ADENOCARCINOMA$0
M01 · FY2000 · RR
HUMANIZED ANTI TAC ANTIBODY THERAPY IN LEUKEMIA/ LYMPHOM$0
M01 · FY2000 · RR
HUMANIZED ANTI TAC ANTIBODY THERAPY IN LEUKEMIA/ LYMPHOM$0
M01 · FY2000 · RR